Condition: Advanced Solid Tumor · Sponsor: PharmaMar
The first part of the study (phase Ia - dose escalation) will evaluate the safety and tolerability and identify the dose-limiting toxicities (DLTs) of PM54. The second part of the study (phase Ib - safety run-in and expansion) will be to reassess the maximum tolerated dose (MTD) defined in the Phase Ia stage in a framework of more extensive premedication, and to evaluate the antitumor activity of PM54 according to the RECIST v.1.1 (or mRECIST v.1.1 in case of MPM) and/or serum markers as appropriate, in patients with selected advanced solid tumors.
This description comes directly from the study's public registry record.
Cristian M Fernández, M.D. · + 34 91 846 6077 · cmfernandez@pharmamar.com
Gaston Federico Boggio, M.D. · +34 91 823 4524 · gfboggio@pharmamar.com
Always discuss trial participation with your own doctor first.
| South Texas Accelerated Research Therapeutics | San Antonio, Texas, United States | Recruiting |
| Institut Jules Bordet | Anderlecht, Belgium | Recruiting |
| HM Universitario Sanchinarro | Madrid, M, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05841563